Cargando…
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
BACKGROUND: Type 1 diabetes mellitus (T1DM) is a rare, but serious immune-related adverse event (irAE) of immune checkpoint inhibitors (ICIs). Our goal was to characterize treatment outcomes associated with ICI-induced T1DM through analysis of clinical, immunological and proteomic data. METHODS: Thi...
Autores principales: | Marsiglio, John, McPherson, Jordan P., Kovacsovics-Bankowski, Magdalena, Jeter, Joanne, Vaklavas, Christos, Swami, Umang, Grossmann, Douglas, Erickson-Wayman, Alyssa, Soares, Heloisa P., Kerrigan, Katie, Gibson, Berit, Doherty, Jennifer Anne, Hyngstrom, John, Hardikar, Sheetal, Hu-Lieskovan, Siwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475559/ https://www.ncbi.nlm.nih.gov/pubmed/37671166 http://dx.doi.org/10.3389/fimmu.2023.1229823 |
Ejemplares similares
-
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis
por: Williamson, Julie, et al.
Publicado: (2023) -
The dark side of immunotherapy
por: Okwundu, Nwanneka, et al.
Publicado: (2021) -
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
por: Pokorny, Rebecca, et al.
Publicado: (2021) -
Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019) -
What does PD-L1 positive or negative mean?
por: Ribas, Antoni, et al.
Publicado: (2016)